FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin

INCHEON, South Korea& JERUSALEM--(BUSINESS WIRE) December 14, 2018 --Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb), a HER2/neu...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news